Aerosol Biology Small Animal Models

$389,577U54FY2013AINIH

Washington University, Saint Louis MO

Investigators

Linked publications & trials

Paper 35873156 Paper 31990686 Paper 31092684 Paper 30593637 Paper 29555731 Paper 29063667 Paper 28874468 Paper 28550119 Paper 28110145 Paper 27779193 Paper 27468281 Paper 27274048 Paper 27226371 Paper 27122575 Paper 26787880 Paper 26730950 Paper 26671708 Paper 26655238 Paper 26479788 Paper 26157117 Paper 26132196 Paper 26010977 Paper 26010249 Paper 25999917 Paper 25975198 Paper 25764399 Paper 25757571 Paper 25756647 Paper 25619688 Paper 25561542 Paper 25520507 Paper 25437230 Paper 25410872 Paper 25295729 Paper 25266349 Paper 25262473 Paper 25200953 Paper 25136083 Paper 25078919 Paper 24983375 Paper 24968940 Paper 24954476 Paper 24943221 Paper 24885416 Paper 24762827 Paper 24743696 Paper 24728596 Paper 24725928 Paper 24679532 Paper 24618256 Paper 24606692 Paper 24495995 Paper 24452684 Paper 24418550 Paper 24352446 Paper 24335291 Paper 24310610 Paper 24286610 Paper 24284630 Paper 24173234 Paper 24167629 Paper 24067086 Paper 24048899 Paper 24048526 Paper 24011765 Paper 24010825 Paper 24006442 Paper 23962002 Paper 23918369 Paper 23918215 Paper 23860770 Paper 23860224 Paper 23838821 Paper 23833237 Paper 23729477 Paper 23716606 Paper 23658447 Paper 23633479 Paper 23580529 Paper 23545571 Paper 23518336 Paper 23515536 Paper 23487461 Paper 23487367 Paper 23426631 Paper 23408632 Paper 23364696 Paper 23341590 Paper 23314004 Paper 23312338 Paper 23300459 Paper 23276405 Paper 23275090 Paper 23264053 Paper 23248310 Paper 23209377 Paper 23115296 Paper 23115291 Paper 23115038 Paper 23112205

Abstract

During the first award period the MRCE Aerosol Biology/Small Animal Models Core D (Core D) supported smallpox disease research (using ectromelia, monkeypox, and vaccinia viruses) as this disease was one of the most intensely modeled in Region 7. With licensure of Modified Vaccinia Ankara (MVA) and the availability of ACAM 2000¿ (derived from Dryvax¿), and phase I clinical trials of orthopoxvirus antivirals, ST-246 and CMX001, there is a diminishing need for in vivo testing of additional orthopoxvirus therapeutics and prophylactics. There is, however, still much to learn concerning the innate immune response to orthopxviruses and other infectious agents. The capacity of Core D to create additional models for use in basic research and prophylactic and therapeutic efficacy testing was under-scored by the development of the following five lethal challenge models: influenza virus A in C57BL/6-sfaH

View original record on NIH RePORTER →